

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**POSITIVE PROFIT ALERT**

This announcement is issued by Sisram Medical Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended June 30, 2021 (the “**Period**”) and the information currently available to the Board, the Group is expected to record significant increases of more than 73% in its revenue for the Period and more than 190% in its profits for the Period, in each case, as compared to that for the corresponding period in 2020.

The expected significant increases in revenue and profits for the Period are mainly attributable to the Group’s (i) global operation spanning across over 90 countries and regions worldwide, which facilitated the agility and mitigation of markets dynamics, (ii) strong position in its two leading markets: North America and China, (iii) resilience strategy, focused on retaining talents and company resources during the pandemic, (iv) strong synergistic collaboration between diverse product lines and distribution channels in the global medical aesthetics market, and (v) strong research and development capabilities, evidenced by the introduction of new technologies and the upgrade of existing ones.

The Board reminds Shareholders and potential investors that the information contained in this announcement has not been reviewed or audited by the independent auditor or the audit committee of the Company and may subject to adjustment. The actual results of the Company for the Period may differ from the information contained in this announcement. Detailed financial information of the Company for the Period will be disclosed in the interim results announcement of the Company for the Period, which is expected to be published before the end of August 2021.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, July 5, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* *for identification purpose only*